Further screening of two public PPGL data sets [17,18] revealed three additional MYO5B mutations; one germline mutation in a metastatic PCC (p.R1641C), and two mutations in PCC tumor cases with metastatic potential (PASS score = 10) [19] or metastasized disease [18] (p.V1261G and p.D530E respectively). Here, MYO5B is linked to neoplasm.